SEC Form 8-K Summary
Registrant: Tivic Health Systems, Inc. (Nasdaq: TIVC), although the request metadata identifies Valion Bio, Inc. The filing was dated April 5, 2022, with the earliest reported events occurring April 1, 2022.
Business Context and Reporting Period
This Form 8-K reports executive management changes and related employment arrangements. It is not a periodic financial-results filing and does not provide quarterly or annual operating results.
Key Financial and Operating Metrics
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, cash balance, or other financial performance metrics.
- Veronica Cai was appointed Chief Financial Officer at an annual base salary of $325,000 and may receive a discretionary annual bonus of up to 25% of base salary.
- Ryan Sabia, Chief Operating Officer, entered into an employment agreement providing an annual base salary of $250,000 and eligibility for a discretionary annual bonus of up to 25% of base salary.
- Ms. Cai received options for 117,880 common shares with a $1.61 exercise price, a 10-year term, and vesting beginning April 1, 2023, with the remainder vesting monthly over 36 months.
- The company repurchased 93,750 unvested restricted shares from former CFO Briana Benz for $375, or $0.004 per share.
Material Changes Versus the Prior Comparable Period
- Briana Benz resigned as Chief Financial Officer effective April 1, 2022, to pursue other opportunities. Her employment agreement terminated on that date.
- Ms. Benz stated that her resignation was not due to disagreement with the company regarding operations, policies, or practices.
- Veronica Cai became Chief Financial Officer effective April 1, 2022.
- The company entered into a new executive offer letter with Chief Operating Officer Ryan Sabia on April 1, 2022.
Guidance, Outlook, Risks, and Unusual Items
- No revenue or earnings guidance was provided.
- The new executive arrangements are at-will. If Ms. Cai or Mr. Sabia terminates employment for good reason, or the company terminates employment without cause, the applicable executive may receive six months of base salary continuation and six months of COBRA coverage, subject to the agreement terms.
- No separation benefits are payable under specified circumstances, including termination for cause, resignation other than for good reason, death, or disability.
- The filing includes customary warnings that forward-looking statements are subject to business, operating, financial, and other risks that could cause actual results to differ materially.
- The filing does not identify a specific contingency, dispute, or operational issue associated with Ms. Benz’s resignation.
Important Facts for Investors to Verify
- Confirm the correct issuer: the filing identifies Tivic Health Systems, Inc., not Valion Bio, Inc.
- Review Exhibits 10.1 and 10.2 for the complete terms of the Cai and Sabia employment agreements.
- Assess the effect of the CFO transition on financial reporting, internal controls, fundraising, and strategic execution.
- Evaluate potential dilution and expense associated with the 117,880 stock options granted to Ms. Cai.
- Consult the company’s periodic filings for current revenue, cash, liquidity, debt, operating losses, and going-concern or financing disclosures, none of which are provided in this 8-K.